Phase II Study of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
British Journal of Haematology - United Kingdom
doi 10.1111/bjh.14536
Full Text
Open PDFAbstract
Available in full text
Categories
Date
February 7, 2017
Authors
Publisher
Wiley